Effects of essential periodontal treatment on serum level of sCD40L and periodontal clinical parameters in patients with moderate to severe periodontitis at high risk of stroke

Abstract

Abstract: PURPOSE: To investigate the effect of periodontal treatment on patients with moderate to severe periodontitis at high risk of stroke, by detecting the level of serum soluble cell differentiation antigen 40 ligand (sCD40L) before and after periodontal non-surgical treatment. METHODS: Seventy-six patients with moderate to severe periodontitis at high risk of stroke were collected and randomly divided into 2 groups, 40 patients in group A received essential periodontal treatment + routine maintenance therapy, 36 cases in group B only received routine maintenance therapy. Another 36 patients with moderate and severe periodontitis were selected as group C, and received essential periodontal treatment. Bleeding on probing (BOP), periodontal probing depth (PD) and attachment loss (AL) in 6 loci were examined by the same dentists, and enzyme linked immunosorbent assay (ELISA) was used to detect the level of serum sCD40L before treatment and 3 months after treatment. The data were analyzed by SPSS 17.0 software package. RESULTS: Compared with pre-treatment, serum level of sCD40L and periodontal clinical indexes of the three groups decreased. Compared with group B, serum SCD40L in group A significantly decreased(P<0.05). CONCLUSIONS: Periodontal treatment can reduce the serum level of sCD40L in patients with moderate to severe periodontitis at high risk of stroke, and improve the patient's inflammatory state. To a certain extent, periodontal treatment may reduce the risk of high-risk stroke population to develop stroke.

Key words: Essential periodontal treatment, Patients with high risk of stroke, Moderate to severe periodontitis, sCD40 ligand (sCD40L), Periodontal clinical parameters

CLC Number:

R781.4

GAO Lei, SUN Xiao-ju, XIE Hong, NAN Shun-hua, XIE Hui-xin. Effects of essential periodontal treatment on serum level of sCD40L and periodontal clinical parameters in patients with moderate to severe periodontitis at high risk of stroke[J]. Shanghai Journal of Stomatology, 2016, 25(5): 574-578.

References

[1] 孟焕新. 牙周病学[M].第4版.北京: 人民卫生出版社, 2012: 12.
[2] 陈红岩, 孙晓菊, 谢洪, 等. 慢性牙周炎与脑血栓形成相关性研究 [J]. 中国实用口腔科杂志, 2010, 3(3): 164-166.
[3] Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction [J]. Periodontol 2000, 1997, 14: 9-11.
[4] Teng YT. The role of acquired immunity and periodontal disease progression [J]. Crit Rev Oral Biol Med, 2003, 14(4): 237-252.
[5] Yamazaki K, Yoshie H, Seymour GJ. T cell regulation of the immune response to infection in periodontal diseases [J]. Histol Histopathol, 2003, 18(3): 889-896.
[6] Mathur A, Michalowicz BS. Cell-mediated immune system regulation in periodontal diseases [J]. Crit Rev Oral Biol Med, 1997, 8(1): 76-89.
[7] Chaturvedi R, Gupta M, Jain A, et al. Soluble CD40 ligand: a novel biomarker in the pathogenesis of periodontal disease [J]. Clin Oral Investig, 2015, 19(1): 45-52.
[8] Schönbeck U, Mach F, Libby P. CD154 (CD 40 ligand )[J]. Int J Biochem Cell Biol, 2000, 32(30): 687-693.
[9] Freedman JE. CD40-CD40L and platelet function: beyond hemostasis [J]. Circ Res, 2003, 92(9): 944-946.
[10] Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J]. Nature, 1998, 391(6667): 591-594.
[11] André P, Prasad KS, Denis CV, et al. CDL stabilizes artefial thrombi by a 63 integrin-dependent mechanism [J]. Nat Med, 2002, 8(3): 247-252.
[12] Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system [J]. Proc Natl Acad Sci USA, 2000, 97(13): 6930-6932.
[13] Zhou L, Stordeur P, de Lavareille A, et al. CD40 engagement on endothelial cells promotes tissue factor dependent procoagulant activity [J]. Thromb Haemostat, 1998, 79(5): 1025-1028.
[14] Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes[J]. N Engl J Med, 2003, 348(12): 1104-1111.
[15] Balla J, Magyar MT, Bereczki D, et al. Serum levels of platelet released CD40 ligand are increased in early onset occlusive carotid artery disease [J]. Dis Markers, 2006, 22(3): 133-140.
[16] Schönbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women [J]. Circulation, 2001, 104(19): 2266-2268.
[17] 陈亚锋, 邓长金, 胡迎富, 等.普伐他汀对高胆固醇血症患者CD40配体的影响 [J].微循环学杂志, 2009, 19(1): 31-33.
[18] 黄载文. 缺血性脑卒中的危险因素研究进展 [J]. 中国医药指南, 2013, 11(11): 60-61.
[19] 曹承兰, 余年, 林兴建, 等. 脑卒中高危人群的相关危险因素 [J].临床神经病学杂志, 2014, 27(5): 335-337.
[20] Mach F, Schönbeck U, Sukhova GK, et al. Functional CD40 and is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40 ligand signaling in atherosclerosis [J]. Proc Natl Acad Sci USA, 1997, 94(5): 1931-1936.
[21] Häkkinen T, Karkola K, Ylä-Herttuala S, et al. Macrophages, smooth muscle cells, endothelial cells, and T cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Coloealization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CDl6 (Fc gammaRIII) [J]. Virchows Arch, 2000, 437(4): 396-405.
[22] Schönbeck U, Mach F, Sukhoa GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth cells by T lymphocytes: a role for CD40 signaling in plaque rupture [J]. Circ Res, 1997, 81(3): 448-454.
[23] Sehönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice [J]. Proc Natl Acad Sci USA, 2000, 97(13): 7458-7463.
[24] Papapanagiotou D, Nicu EA, Bizzarro S, et al. Periodontitis is associated with platelet activation[J]. Atherosclerosis, 2009, 202(2): 605-611.
[25] Angulo P. Nonalcoholic fatty liver disease [J]. N Engl J Med, 2002, 346(16): 1221-1231.
[26] Herm V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J]. Nature, 1998, 391(6667): 591-594.